Moderna CEO Says Its Coronavirus Vaccine Will Be Affordable

As the COVID-19 epidemic continues to spread, demand keeps growing for effective treatments and vaccines. Moderna (NASDAQ: MRNA), one of the only companies with a vaccine in clinical trials for SARS-CoV-2 (the coronavirus that causes the disease), made news Wednesday when its CEO said that his company's vaccine would be affordably priced.

Stephane Bancel said in an interview with Business Insider that he plans to price the SARS-CoV-2 vaccine, known as mRNA-1273, in line with other vaccines for respiratory infections. Although he didn't offer an exact figure, one can look to prices for other vaccines, such as a pneumonia treatment, Prevnar 13 which has an average cost of around $240, to get a rough idea of what Bancel might be thinking.

Image source: Getty Images.

Continue reading

Source Fool.com